Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc. develops and commercializes therapies for neurological and rare diseases. Its commercial portfolio includes NUPLAZID (pimavanserin) for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE (trofinetide), including DAYBUE STIX, for Rett syndrome.
Company news commonly covers product revenue from NUPLAZID and DAYBUE, formulation and launch updates for trofinetide, clinical and scientific presentations across neurological disorders, pipeline work in Alzheimer’s disease psychosis, Lewy body dementia psychosis and essential tremor, investor-conference participation, and board or research-and-development leadership changes.
Acadia Pharmaceuticals (Nasdaq: ACAD) reported second quarter 2026 GAAP total revenues of $308 million, up 16% year-over-year and 17% versus non-GAAP adjusted 2Q25. NUPLAZID® GAAP net sales were $183 million (up 9% vs GAAP, 10% vs non-GAAP), and DAYBUE® net sales were $125 million, up 30% year-over-year, driven by strong uptake of DAYBUE STIX.
Net income was $31.5 million, or $0.18 per diluted share, compared to $26.7 million and $0.16 a year ago. Cash, cash equivalents and investment securities rose to $956 million from $820 million at year-end 2025. Acadia raised 2026 total revenue guidance to $1.24–$1.30 billion, increased DAYBUE guidance to $480–$510 million, reaffirmed NUPLAZID guidance of $760–$790 million, and lowered R&D expense guidance to $355–$380 million. The company completed Phase 2 enrollment and started Phase 3 screening for remlifanserin in Alzheimer’s disease psychosis, obtained FDA Fast Track designation, and received a positive CHMP opinion recommending EU approval for DAYBU.
Acadia Pharmaceuticals (Nasdaq: ACAD) will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 1:30 p.m. Eastern Time. A live webcast and a one‑month archive will be available in the investors section of acadia.com.
Acadia Pharmaceuticals (Nasdaq: ACAD) announced that the U.S. FDA has granted Fast Track designation to remlifanserin (ACP-204), an investigational, highly selective 5-HT2A receptor inverse agonist, for treating hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP), a serious condition with no FDA-approved therapies.
According to Acadia, enrollment in the RADIANT Phase 2 program evaluating remlifanserin in ADP is now complete, with topline results expected in September–October 2026. The company reports that, consistent with RADIANT’s operationally seamless design, Phase 3 screening and enrollment are already underway. Remlifanserin is also being developed for Lewy body–associated psychosis and is intended to modulate 5-HT2A signaling without direct dopamine D2 blockade, which may help avoid safety and tolerability issues seen with atypical antipsychotics.
Acadia Pharmaceuticals (Nasdaq: ACAD) plans to report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the U.S. market close. Management will host a conference call and webcast the same day at 4:30 p.m. Eastern Time, accessible via registration and through the investors section of acadia.com.
The webcast will be archived for approximately 90 days. Acadia focuses on treatments for Parkinson’s disease psychosis and Rett syndrome and is developing therapies for Alzheimer’s disease psychosis, Lewy body dementia psychosis, and other neurological and rare diseases.
Acadia Pharmaceuticals (Nasdaq: ACAD) appointed Carl Segerstrom as Chief People Officer, effective July 6. He will lead global people and culture strategy and join the executive leadership team.
Segerstrom brings over 25 years of biopharma HR experience, including senior leadership roles at Merck, Pharmacia, Schering-Plough and Pfizer.
Acadia (Nasdaq: ACAD) announced that EMA’s CHMP adopted a positive opinion, after re-examination, recommending EU marketing authorization for DAYBU (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and children ≥5 years. If approved by the European Commission, DAYBU would be the first therapy for this indication across the EU and EEA, supported by Phase 3 LAVENDER data showing statistically significant, clinically meaningful improvements on RSBQ and CGI-I scales.
Acadia Pharmaceuticals (Nasdaq: ACAD) reported Q1 2026 GAAP total revenues of $268 million, driven by DAYBUE net sales of $101 million (+20% YoY) and NUPLAZID net sales of $167 million (+5% GAAP YoY). The company reaffirmed full‑year 2026 GAAP revenue guidance of $1.22–$1.28 billion and expects Phase 2 remlifanserin topline data in Alzheimer’s disease psychosis in Aug–Oct 2026.
Q1 net income was $4 million and cash and investments totaled $851 million at March 31, 2026.
Summary not available.
Acadia Pharmaceuticals (NASDAQ: ACAD) will present at two investor conferences in May 2026: a BofA Securities Health Care Conference fireside chat on May 12, 2026 at 4:20 p.m. PT in Las Vegas and an RBC Capital Markets Global Healthcare Conference fireside chat on May 19, 2026 at 9:00 a.m. ET in New York.
Live webcasts will be available on the company website and archived for roughly one month after each presentation. Acadia highlights its commercial portfolio, including FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome, and its pipeline in Alzheimer’s disease psychosis and Lewy body dementia psychosis.
Acadia Pharmaceuticals (Nasdaq: ACAD) will present multiple original data presentations at the 2026 AAN Annual Meeting, April 18–22 in Chicago.
Presentations include Phase 4 real-world LOTUS data on DAYBUE (trofinetide) in adults with Rett syndrome, exploratory pimavanserin (NUPLAZID) analyses in Parkinson’s disease psychosis, and translational and pharmacokinetic research for investigational ACP-711 in essential tremor.
Poster sessions are scheduled April 21–22 with specific poster IDs and times listed for each study.